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Summary
To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 
three genome-wide association studies (GWAS) and two independent datasets genotyped on the 
Immunochip, involving 10,588 cases and 22,806 controls in total. We identified 15 new disease 
susceptibility regions, increasing the number of psoriasis-associated loci to 36 for Caucasians. 
Conditional analyses identified five independent signals within previously known loci. The newly 
identified shared disease regions encompassed a number of genes whose products regulate T-cell 
function (e.g. RUNX3, TAGAP and STAT3). The new psoriasis-specific regions were notable for 
candidate genes whose products are involved in innate host defense, encoding proteins with roles 
in interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C), and NF-
κB signaling (CARD14 and CARM1). These results portend a better understanding of shared and 
distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the 
importance of the skin in innate and acquired host defense.
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
‡Corresponding authors: Richard C. Trembath, Division of Genetics and Molecular Medicine, King’s College London School of 
Medicine, Guy’s Hospital, London SE1 9RT. UK; Queen Mary University of London, Barts and the London School of Medicine and 
Dentistry, London E1 2AD, UK, vp-health@qmul.ac.uk. Goncalo R. Abecasis, Department of Biostatistics, School of Public Health 
M4614 SPH I, University of Michigan, Box 2029, Ann Arbor, MI 48109-2029, USA, phone (734) 763-4901, goncalo@umich.edu. 
James T. Elder, 7412 Medical Sciences Building 1, University of Michigan Medical School, 1301 E. Catherine, Ann Arbor, Michigan 
48109-5675, USA, phone (734) 647-8070, jelder@umich.edu.
*These authors contributed equally to this work
49A list of members and affiliations appears in the Supplementary Note
AUTHOR CONTRIBUTIONS
J.T.E., R.C.T. and G.R.A. designed and directed the study. R.P.N., M.W., J.D., J.V., J.T.E., F.C., J.N.B., M.A., C.S., A.D.B., C.G., 
A.R., J.Ke., X.E., W.W., J.Wo., R.T-A., M.S., G.N., L.S., R.M., M.C., J.S., A.F., S.W., S.K., K.K., T.E., A.M., A.B., G.K., D.G., 
P.R., U.M., F.N., A.H., J.W., S.S., C.W., C.L., S.E., R.A., V.C., and C.F.R., and H.B. contributed to sample collection and 
phenotyping. J.K. coordinated the GAP consortium’s samples and datasets. J.T.E. coordinated the PAGE samples and datasets. P.De., 
A.S., G.B., R.D.P., D.V., and C.C.A.S. contributed to the design of the Immunochip. J.K., P.E.S, G.R.A., and H.M.K. advised on the 
statistical analysis. C.L., S.E., R.A., H.B., E.E., P.H., and R.P.N. performed genotyping. E.E., S.L.S., L.C.T., and H.M.K. performed 
the genotype calling. S.L.S., L.C.T., Y.L., and D.J. performed genotype imputation and statistical analysis. F.C., J.N.B., J.E.G., T.T., 
J.T.E., and A.F. prepared Box 1. L.C.T., S.L.S., F.C. and J.T.E. drafted the manuscript, and prepared the figures and tables. E.E., 
J.E.G., J.K., P.E.S., R.P.N., R.C.T., T.T., G.R.A., J.N.K., and A.F. edited and revised the manuscript. All authors approved the final 
draft.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Note: Supplementary information is available on the Nature Genetics website.
URLs
WTCCC common controls: http://www.wtccc.org.uk 1000 Genomes Project data are available at: ftp://ftp.1000genomes.ebi.ac.uk/
vol1/ftp/release/20100804/ National Human Genome Research Institute (NHGRI) GWAS catalog: http://www.genome.gov/
gwastudies eQTL database: http://www.sph.umich.edu/csg/junding/eQTL/TableDownload/
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
HHS Public Access
Author manuscript
Nat Genet. Author manuscript; available in PMC 2013 June 01.
Published in final edited form as:
Nat Genet. 2012 December ; 44(12): 1341–1348. doi:10.1038/ng.2467.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Psoriasis is a chronic, potentially disfiguring, immune-mediated inflammatory disease of the 
skin with a prevalence of 0.2 to 2%, depending on the population of origin. About one-
quarter of psoriatics develop a painful and debilitating arthritis, and there is increasing 
awareness of co-morbidities, including metabolic syndrome and cardiovascular disease1,2. 
Current evidence suggests that a dysregulated cutaneous immune response characterized by 
tumor necrosis factor-α (TNF) dependence and exaggerated Th1 and Th17 activation occurs 
in genetically susceptible individuals1,2. Recent large-scale association studies have 
identified 26 loci that are associated with psoriasis3–10, 21 of which show association in 
Caucasians3–6,10. Several of these signals overlap with other autoimmune diseases (e.g. 
Crohn’s disease, ankylosing spondylitis, and celiac disease), particularly those near genes 
involved in Th17 differentiation and IL-17 responsiveness (e.g. IL23R, IL12B, IL23A, 
TRAF3IP2)11. To accelerate our understanding of the genetic architecture of this disease, we 
helped design a custom single-nucleotide polymorphism (SNP) array (the “Immunochip”). 
The aims of the Immunochip are to fine-map genome-wide significant (i.e. P<5×10−8) 
susceptibility loci and to explore replication of thousands of SNPs representing additional 
promising signals12,13. In this study, we use Immunochip data to identify new genetic 
determinants of psoriasis, and to relate them to other autoimmune disorders.
We combined three existing GWAS datasets (hereafter referred to as Kiel3, CASP4 and 
WTCCC25) with two independent European-descent case-control datasets genotyped on the 
Immunochip: the Psoriasis Association Genetics Extension (PAGE: 3,580 cases and 5,902 
controls) and the Genetic Analysis of Psoriasis Consortium (GAPC: 2,997 cases and 9,183 
controls) (datasets are described in Supplementary Tables 1 and 2). After quality control, the 
combined dataset consisted of 10,588 patients with psoriasis and 22,806 healthy controls. 
For each GWAS, we increased the SNP density through imputation by using European 
haplotype sequences generated by the 1000 Genomes Project as templates (20100804 
release). Overall, our analysis includes 111,236 SNPs that were genotyped in both 
Immunochip datasets and also had good imputation quality in at least two of the three 
GWAS (see Online Methods).
Meta-analysis of all five datasets yielded genome-wide significance for 19 of the 21 known 
psoriasis loci (Supplementary Fig 1, Table 1, Supplementary Table 3). We found nominal 
evidence for the remaining two loci in the combined analysis (ZMIZ1 and PRDX5, each with 
P < 3×10−6) as well as nominal evidence for all loci in separate analyses including only 
GWAS (all with P < 5×10−3) or Immunochip data (all with P < 4×10−4). In addition, we 
identified 15 new risk loci at P < 5×10−8 (Supplementary Fig 1, Table 1, and Supplementary 
Table 3). Nine of the new signals were submitted, during design of the Immunochip, as 
genome-wide significant Immunochip loci by at least one other disease consortium (see 
“Disease Overlap” column in Supplementary Table 4), though we also submitted three of 
these (rs11121129, rs10865331, and rs9504361) based on a preliminary meta-analysis of our 
GWAS datasets. Notably, of the remaining six signals, four were submitted as genome-wide 
significant loci for psoriasis (SNPs rs11795343, rs4561177, rs11652075, and rs545979). The 
strongest new association was observed for rs892085 at 19p13.2, near the ILF3 and CARM1 
genes (combined Pvalue (Pcomb) = 3.0 × 10−17; OR = 1.17). Despite its proximity (< 500kb) 
to TYK2, conditional analysis demonstrated that this is an independent signal 
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(Supplementary Table 5). Other associated loci included 1p36.11 near RUNX3; 6p25.3 near 
EXOC2 and IRF4; 9p21.1 near DDX58; 11q22.3 near ZC3H12C, 11q24.3 in the ETS1 gene 
and 17q21.2 near STAT3, STAT5A and STAT5B. Box 1 summarizes the functional 
characteristics of notable genes from the newly identified loci, and the regional association 
plots are shown in Supplementary Fig 2.
Box 1
The function of notable genes in the regions of newly identified 
associations
RERE, SLC45A1, ERRFI1, TNFRSF9 (1p36.23)
This signal falls between the RERE, SLC45A1, ERRFI1, and TNFRSF9 genes. RERE 
encodes an arginine-glutamic acid dipeptide repeat-containing protein that controls 
retinoic acid signalling38. ERRFI1 encodes a feedback inhibitor of the EGF receptor39. 
SLC45A1 encodes a solute carrier protein that mediates the uptake of glucose40. The 
TNFRSF9 gene encodes a co-stimulatory molecule that has a role in generation of 
memory CD8+ T-cells.
RUNX3 (1p36.11)
RUNX3 is a member of the Runt domain-containing family of transcription factors and 
has an essential role in T-cell biology, particularly in the generation of CD8+ cells. 
RUNX3 also has a role in promoting Th1 differentiation through binding with T-bet41.
B3GNT2 (2p15)
B3GNT2 is a member of the beta-1,3-N-acetylglucosaminyl transferase family. It 
catalyzes the initiation and elongation of poly-N-acetyllactosamine chains42. Deficiency 
has shown to results in hyperactivation of lymphocytes43.
EXOC2, IRF4 (6p25.3)
EXOC2 encodes a component of the multi-protein complex which mediates the docking 
of exocytic vesicles to the plasma membrane44. IRF4 encodes a transcription factor that 
regulates IL17A promoter activity and controls RORyt-dependent Th17 colitis in 
vivo45,46. IRF4 also plays a role in stabilization of the Th17 phenotype through IL-2147 
and may regulate CD4/CD8 differentiation through regulation of RUNX3 expression48.
TAGAP (6q25.3)
This gene is a Rho-GTPase activating protein that is involved in T-cell activation49.
ELMO1 (7p14.2-7p14.1)
ELMO1 is a member of the engulfment and cell motility protein family, which binds to 
DOCK2, and is essential for TLR7- and TLR9-mediated IFN-α induction by plasmacytoid 
dendritic cells50 and plasmacytoid dendritic cell migration.51 DOCK2 also has a role in 
antigen-uptake and presentation, and lymphocyte trafficking51.
DDX58 (9p21.1)
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DDX58 encodes the RIG-I innate antiviral receptor, which recognizes cytosolic double-
stranded RNA.52 It is induced by IFN-γ53 and regulates type I and type II IFN 
production54.
KLF4 (9p31.2)
KLF4 is a Kruppel-like transcription factor, which is required for the establishment of 
skin barrier function55 and regulates key signaling pathways related to macrophage 
activation56. KLF4 also binds to the promoter of IL17A and positively regulates its 
expression.
ZC3H12C (11q22.3)
Zinc-finger protein regulating macrophage activation57.
ETS1 (11q24.3)
Transcription factor activated downstream of the Ras-MAPK pathway, involved in 
homeostasis of squamous epithelia58. Involved in CD8 lineage differentiation and acts in 
part by promoting RUNX3 expression59. Negative regulator of Th17 differentiation60
SOCS1 (16p13.13)
SOCS1 is a member of the suppressor of cytokine signalling family of proteins and 
inhibits signalling events downstream of IFN-γ61. It regulates Th17 differentiation by 
maintaining STAT3 transcriptional activity62 and interacts with TYK2 in cytokine 
signalling63.
STAT3 , STAT5A/5B (17q21.2)
STAT3 and STAT5A/5B are members of the STAT family of transcription activators. 
STAT3 participates in signalling downstream of multiple cytokines implicated in psoriasis 
such as IL-6, IL-10, IL-20, IL-22 and IL-23 and may have a role in mediating the innate 
immune response in psoriatic epidermis64. STAT3 is required for the differentiation of 
Th17 cells65. STAT5A/5B participate in signalling downstream of the IL-2 family of 
cytokines, including IL-2, IL-7, IL-15 and IL-21. Both proteins contribute to the 
development of Treg cells and inhibit the differentiation of Th17 cells66.
CARD14 (17q25.3)
Member of a family of Caspase Recruitment Domain containing scaffold proteins, known 
as CARD- and membrane-associated guanylate kinase-like domain-containing protein 
(CARMA). CARD14/CARMA2 is primarily expressed in epithelial tissues and mediates 
recruitment and activation of the NF-κB pathway67.
MBD2,POLI ,STARD6 (18q21.2)
MBD2 is a transcriptional repressor that binds to methylated DNA and has a role in the 
generation of memory CD8+ T-cells68. POLI is an error-prone DNA polymerase, which 
contributes to the hyper-mutation of immunoglobulin genes69. Sterol transport is 
mediated by vesicles or by soluble protein carriers, such as steroidogenic acute regulatory 
protein (STAR; MIM 600617). STAR is homologous to a family of proteins containing a 
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200- to 210-amino acid STAR-related lipid transfer (START) domain, including 
STARD6.
ILF3, CARM1 (19p13.2)
ILF3 encodes a double-stranded RNA (dsRNA) binding protein that complexes with 
other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression 
and stabilize mRNAs. It is a subunit of the nuclear factor of activated T-cells (NFAT); a 
transcription factor required for T-cell expression of IL-2. CARM1 is a transcriptional 
coactivator of NF-κB and functions as a promoter-specific regulatory of NF-κB 
recruitment to chromatin.
To identify independent secondary signals, we performed conditional analysis using as 
covariates the strongest signals from the 34 loci achieving genome-wide significance in this 
study. We identified secondary signals in five loci: 2q24.2, 5q15, 5q33.3, 6p21.33, and 
19q13.2 (Supplementary Figs. 3 and 4, Supplementary Tables 6 and 7). The strongest signal 
from the conditional analysis maps to the MHC region near the MICA gene (rs13437088: 
P=3.1 × 10−40; OR = 1.32), in agreement with a previous conditional analysis14. The 5q15 
conditional signal is in the ERAP2 gene (rs2910686: P = 2.0 × 10−8), which did not show 
any evidence of association in the unconditional analysis (P = 0.46). Further investigation 
revealed that the risk-increasing alleles at ERAP1 and the risk-decreasing alleles at ERAP2 
preferentially appear on the same haplotype, and the signal near ERAP2 is thus masked by 
ERAP1 prior to conditional analysis (Supplementary Note). The strongest conditional signal 
in the 19q13.2 region was rs12720356 in the TYK2 gene (OR=1.25, MAFcontrols=0.09, P = 
3.2 × 10−10). The association of this SNP with psoriasis has been previously reported5 and is 
independent of the strongest TYK2 signal identified by our meta-analysis (rs34536443, 
OR=1.88, MAFcases=0.03, P = 1.5 × 10−39). As rs34536443 was a low-frequency imputed 
SNP and manifested the highest effect size outside of the MHC, we directly genotyped this 
SNP in 3,390 independent Michigan samples (1,844 cases and 1,546 controls), robustly 
replicating the association (OR = 2.80, MAFcases= 0.02, P = 7.8 × 10−14) and experimentally 
confirming the validity of our imputation procedures.
We next tested for statistical interaction among the top SNPs in the 34 significant loci 
(Supplementary Note; Supplementary Table 8). We identified two significant pairwise 
interactions after correction for multiple testing (P < 5 × 10−5): HLA-C (rs4406273)-LCE 
(rs6677595) and HLA-C (rs4406273)-ERAP1 (rs27432). These interactions confirm results 
of previous studies5,15,16.
In order to identify potential causal alleles in coding sequence, we looked for missense 
variants in tight LD (r2>0.9 in 1000 Genomes Project European samples) with the lead SNPs 
from each of the 34 identified loci (Table 1 and Supplementary Table 6). We found 10 
potentially causal SNPs (Table 2), nine of which were included in our meta-analysis. For the 
known loci near TRAF3IP2 and TYK2, damaging non-synonymous substitutions were 
themselves the index SNPs in our initial and conditional analyses. Among the newly 
identified loci, the index SNP from CARD14, a gene that harbors Mendelian variants 
predisposing to psoriasis17, was also a common and damaging variant as has been described 
elsewhere18. For the remaining loci, we could account for essentially all index SNP signals 
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by conditioning on nearby missense SNPs, consistent with the possibility that they are 
causal. Notable non-synonymous variants include the protective c.R381Q polymorphism in 
IL23R19; a SNP in the PRSS53 gene20, which is also the most highly over-expressed gene in 
psoriatic skin in this locus6; and a variant in YDJC that also increases risk for celiac 
disease21, rheumatoid arthritis22 and Crohn’s disease23.
Utilizing the results of a large-scale study of gene expression in psoriatic vs. normal skin24 , 
we found 14 up-regulated genes (IL12RB2, LCE3D, REL, PUS10, CDSN, PRSS53, PRSS8, 
NOS2, DDX58, ZC3H12C, SOCS1, STAT3, CARD14, IFIH1) and 4 down-regulated genes 
(MICA, RNF114, PTRF, POLI) in the 34 associated regions (FDR<0.05 and fold-
change>1.5 or <0.67; Supplementary Table 9). The number of differentially expressed genes 
in psoriasis susceptibility loci was not greater than expected by chance (P=0.39). None of 
the 34 top SNPs met the Bonferroni corrected (P < 1×10−7) threshold as expression 
quantitative trait loci (eQTL) in skin tissue, as assessed by microarray analysis of mRNA 
levels25. However, rs2910686, one of the five SNPs identified by conditional analysis, was a 
cis-eQTL for ERAP2 in both normal and psoriatic skin (see Supplementary Note for details). 
Genetic control of ERAP2 expression has been noted previously26,27 and has been suggested 
as a determinant of balancing selection at this locus28.
This study increases the number of psoriasis-associated regions in European ancestry 
samples to 36, with conditional analysis increasing the number of independent signals to 41. 
The 39 independent signals with P < 5×10−8 in the current study collectively account for 
14.3% of the total variance in psoriasis risk, or approximately 22% of its estimated 
heritability29 (see Supplementary Table 10 for details), indicating that further genetic 
studies, including fine mapping studies and searches for uncommon susceptibility variants 
are in order.
Sharing of susceptibility loci between autoimmune diseases has been demonstrated 
previously11 and we find similar patterns in this study. Notably, ten of the psoriasis 
susceptibility loci reported here overlap with Crohn’s disease and ten others with celiac 
disease, two diseases that are enriched in individuals with psoriasis30,31 (Supplementary 
Table 4; illustrated in Supplementary Fig. 5). We caution that the statistical significance of 
these overlaps is hard to assess, given the ongoing process of gene discovery for many 
autoimmune disorders and biases in the list of SNPs evaluated for association in this 
experiment.
As the primary interface with the external environment, the skin provides a critical first line 
of host defense to microbial pathogens. Consistent with this function, it possesses a diverse 
and well-conserved set of innate immune mechanisms32,33, which emerged long before the 
development of adaptive immunity34. In this context, we found it interesting that five of the 
six newly identified loci that are thus far uniquely associated with psoriasis are involved in 
innate immune responses (DDX58, KLF4, ZC3H12C, CARD14 and CARM1, Supplementary 
Table 4 and Box 1). Among all confirmed psoriasis susceptibility loci, 11 out of 14 psoriasis 
specific loci (the five listed above along with IL28RA, LCE3D, NOS2, FBXL19, NFKBIA 
and RNF114) encode plausible regulators of innate host defense1,2,35. Conversely, only 6 
out of 20 loci shared with other autoimmune diseases contain genes (REL, IFIH1, TNIP1, 
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TNFAIP3, IRF4 and ELMO1) that contribute to innate immunity. These provisional 
comparisons further illustrate the insights that can be gained by developing and comparing 
complete and well-annotated sets of risk loci for autoimmune disorders.
The known and newly identified psoriasis susceptibility loci implicated by this study encode 
several proteins engaged in the TNF, IL-23, and IL17 signaling pathways targeted by highly 
effective biologic therapies36. Interestingly, our strongest non-MHC signal directly 
implicates TYK2, a druggable target that contributes to several autoimmune diseases. Agents 
targeting the closely related JAK kinases are showing encouraging results in clinical trials37. 
Our findings will help prioritize and interpret the results of sequencing and gene expression 
studies. Further genomic studies will allow us to identify the underlying causal variants 
within psoriasis susceptibility loci and lead to increased understanding of pathogenetic 
mechanisms and new therapeutic targets.
Online Methods
Sample Collections
The samples used in the 3 GWAS data sets (Kiel, CASP and WTCCC2) were previously 
described3–5. Samples of the Psoriasis/Arthritis Genetics Extension (PAGE) and the Genetic 
Analysis of Psoriasis Consortium (GAPC) datasets (Supplementary Table 1 and 2) were 
collected from subjects of European Caucasian descent at the participating institutions after 
obtaining informed consent in adherence with the Declaration of Helsinki Principles. DNA 
was isolated from blood or EBV-immortalized lymphoblastoid cell lines using standard 
methods.
The collections used in the GAPC and PAGE ImmunoChip studies are described in 
Supplementary Table 2.
The samples from GAPC substantially overlapped with those described as replication 
datasets in Strange et al. 20105. All cases had been diagnosed as having psoriasis vulgaris. 
The GAPC cases and the Irish and Spanish controls were genotyped at the Wellcome Trust 
Sanger Institute (WTSI) and all samples were provided by the relevant groups given in 
Supplementary Table 2 and listed in the GAP consortium members list (Supplementary Note 
2). The UK controls were the WTCCC common controls that did not overlap with samples 
included in the original GWA studies (the dataset consisted of 6,740 1958 British Birth 
cohort and 2,900 UK Blood Service samples genotyped at the WTSI and the University of 
Virginia). The German controls were obtained from the PopGen biobank and genotyped at 
the Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel. The 
Finland control data were from the DILGOM (Dietary, Lifestyle, and Genetic determinants 
of Obesity and Metabolic syndrome) collection70. The Irish controls were provided by the 
Irish Blood Transfusion Service / TCD Biobank and the Irish cases collected with the aid of 
the Dublin Centre for Clinical Research. We did not include specific controls from Austria 
or Sweden, but PCA analysis suggested that the cases from these cohorts were well matched 
to the controls from the Netherlands and Germany.
Tsoi et al. Page 7
Nat Genet. Author manuscript; available in PMC 2013 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
For the PAGE Immunochip study, samples also substantially overlapped with previously 
published replication datasets. The German cases (described as a replication dataset in 
Ellinghaus et al. 20103), all samples from the United States and Canada, as well as 439 
Estonian cases from the University of Tartu were genotyped at the Institute of Clinical 
Molecular Biology, Christian-Albrechts-University of Kiel. The respective samples were 
provided by the groups given in Supplementary Table 2 and listed in the PAGE members list 
(Supplementary Note). The German controls were obtained from a population-based sample 
from the general population living in the region of Augsburg, Southern Germany 
(Collaborative Health Research in the Region of Augsburg; KORA S4/F471), which was 
genotyped at the Helmholtz Center in Munich, and from the population-based 
epidemiological Heinz-Nixdorf Recall study (HNR), which was genotyped at the Life and 
Brain Center at the University Clinic in Bonn. The remaining Estonian samples were 
obtained from and genotyped at the Estonian Genome Center University of Tartu (EGCUT).
Genotyping panel and SNPs
The Immunochip is a custom Illumina Infinium high-density array consisting of 196,524 
variants (after Illumina quality control) compiled largely from variants identified in previous 
GWAS of 12 different immune-mediated inflammatory diseases, including psoriasis13. The 
main aims of the Immunochip were deeper replication and fine-mapping of genome-wide 
significant loci, as well as increasing power to promote promising but less significant SNPs 
to genome-wide significance. For fine mapping, SNPs within 0.2 cM on either side of the 
GWAS top SNPs for 186 loci were selected from 1000 Genomes Project72 low coverage 
pilot CEU sequencing data as well as additional variants identified by resequencing from 
groups involved in the chip design. For promotion of promising signals and those not quite 
reaching genome-wide significance, each disease-focused group was allowed to submit 
approximately 3,000 additional SNPs. We submitted 17 of the 19 confirmed genome-wide 
significant psoriasis regions (Table 1) for fine mapping based on a preliminary meta-
analysis of our data, while one of the confirmed signals (IL28RA) and nine of the new 
psoriasis signals (indicated in the “disease overlap” column of Supplementary Table 5) were 
submitted for fine mapping by other disease groups (though we also submitted three of them 
as part of our additional SNP allocation SNPs: rs11121129, rs10865331, and rs9504361). 
Six additional signals were detected based on individual groups additional SNP allocation; 
four of these (rs11795343, rs4561177, rs11652075, and rs545979) were submitted by our 
group. All Immunochip samples were genotyped as described in Illumina’s protocols.
Genotype calling
For the PAGE dataset genotype calling was performed using Illumina’s GenomeStudio Data 
Analysis software and the custom-generated cluster file of Trynka et al. (based on an initial 
clustering of 2000 UK samples with the GenTrain2.0 algorithm and subsequent manual 
readjustment and quality control)13. The genotype calling for the GAPC dataset was 
performed using GenoSNP73 from allele intensities, except for the German, Italian, Dutch 
and Finnish controls, which were called using the same method described for the PAGE 
dataset.
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Imputation
To increase the number of overlapping SNPs between datasets, we performed imputation on 
the 3 GWAS datasets using minimac74 (Kiel and CASP) and IMPUTE275,76 (WTCCC2) 
based on CEU reference haplotypes from the 1000 Genomes Project72; December 2010 
version of the 10/08/04 sequence and alignment release containing 629 individuals of 
European descent). SNPs with low imputation quality (r2 ≤0.3 for minimac, info score < 0.5 
for IMPUTE2) were removed. For all 3 datasets, cases and controls were imputed together.
Sample and genotype quality control
For the Immunochip datasets, we first excluded SNPs with a call rate below 95% or with a 
Hardy-Weinberg p-value < 1 × 10−6. Samples with less than 98% SNP call rates were then 
excluded. Because the Immunochip includes a large proportion of fine-mapping SNPs that 
are associated with autoimmune disease, we used a set of independent SNPs which have p-
values > 0.5 from the meta-analysis of the 3 GWAS datasets as a quality control tool for 
each individual Immunochip dataset. Using the HapMap 3 samples as reference77, we 
performed principal component (PC) analysis to identify and remove samples with non-
European ancestry. We also removed samples with extreme inbreeding coefficients or 
heterozygosity values computed by PLINK78.
To assess possible stratification in the datasets, principal components analysis was also 
performed in each of the Immunochip datasets separately (excluding HapMap). There was 
no evidence of stratification between the cases and controls of each sample group. However, 
as expected, the top principal components (PCs) do separate the samples well by country of 
origin. The use of the top 10 eigenvectors as covariates in the analysis did not completely 
correct for this stratification and so a linear mixed model method (Efficient Mixed-Model 
Association eXpedited (EMMAX)) was used for the association analysis instead. These 
methods have been shown to outperform PCs at correcting for this type of population 
stratification and cryptic relatedness79, which is becoming more common as sample sizes 
get larger and studies comprise of more collaborative efforts.
To identify duplicate pairs or highly related individuals among datasets, we used a panel of 
873 independent SNPs that were genotyped in both the GWAS and Immunochip samples, 
and performed pairwise comparisons using the ‘genome’ function in PLINK78 , with the 
criterion Pi-HAT≥ 0.5. We identified 1,142 (885 from GAPC and 257 from PAGE) related 
sample pairs (mostly duplicates) and removed one sample from each pair. We also removed 
4,828 controls from the UK common ImmunoChip controls owing to duplication in the 
WTCCC2 GWAS sample. For GWAS samples that were duplicated in the Immunochip 
datasets (the majority of duplicates), we removed the samples from the Immunochip datasets 
to keep the previously published datasets intact.
The GWAS datasets underwent quality control as previously described and were analysed 
for association using the top PCs from the previous analyses, as covariates3–5.
We visually checked the signal intensity cluster plots for all SNPs meeting genome-wide 
significance to confirm high quality genotype calling.
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Genomic Control
Genomic control inflation factors for the five datasets were 1.09 (Kiel), 1.06 (CASP), 1.04 
(WTCCC2), 0.99 (PAGE), and 0.96 (GAPC), indicating that population structure and 
cryptic relatedness were adequately controlled for in these datasets. Because the 
Immunochip was designed for deep replication and fine mapping of loci associated with 
autoimmune diseases12, using all independent SNPs from the chip would not give an 
accurate estimate of the genomic control80 (λGC) value. Therefore, we selected common 
(MAF > 0.05) SNPs from the Immunochip that had p-values > 0.5 based on a meta-analysis 
combining the CASP, Kiel, and the WTCCC2 GWAS, and then performed LD-pruning to 
identify an independent SNP set to compute λGC for the association results from the 
Immunochip datasets. Due to the SNP selection bias, the genomic control of the final meta-
analysis was computed using a set of independent SNPs associated with “reading and 
writing ability” (personal communication, J.C. Barrett). We further removed SNPs that were 
within ±500 kb of previously detected psoriasis loci (±3 Mb was used for the MHC region), 
and the remaining 1,426 SNPs yielded a λGC value of 1.11 for the meta-analysis overall. By 
using the λ100081, the genomic control inflation factor for an equivalent study of 1000 cases 
and 1000 controls, the rescaled λ equals 1.01.
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